Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 14, 1152 - 1153 (2008)
doi:10.1038/nm1108-1152
RIG-ing an antitumor response
Fabio Petrocca1 & Judy Lieberman1
- Fabio Petrocca and Judy Lieberman are at the Immune Disease Institute and Department of Pediatrics, Harvard Medical School, 200 Longwood Avenue, Boston, Massachusetts, 02115, USA.
e-mail: lieberman@idi.harvard.edu
Abstract
A small interfering RNA has been engineered to silence an oncogene and activate the immune response simultaneously. The approach shrinks tumors in mice (pages 1256–1263).
Although it is only seven years since RNA interference (RNAi) was shown in mammalian cells, efforts to harness this powerful and specific gene silencing mechanism to treat human illness by knocking down expression of disease-causing genes have proceeded with lightning speed1. Already, a phase 3 study to treat age-related macular degeneration and several phase 2 studies are in progress.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
RNA interference below the immune radarNature Biotechnology News and Views (01 May 2006)
Sensing RNA virus infectionsNature Chemical Biology News and Views (01 Jan 2007)
See all 6 matches for News And ViewsRESEARCH
A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cellsNature Biotechnology Research (01 Jun 2006)
5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanomaNature Medicine Article (01 Nov 2008)
See all 3 matches for Research